UroGen Pharma (URGN) option IV into data
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/11/2026
- Wall St climbs after August inflation report, oil price slide
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but on track for 8% weekly gain on supply concerns; US diesel hits record high
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
UroGen Pharma (URGN) PT Raised to $53.50 at Ladenburg Thalmann
June 14, 2024 6:54 AM EDTLadenburg Thalmann analyst Matthew Kaplan raised the price target on UroGen Pharma (NASDAQ: URGN) to $53.50 (from $48.00) while maintaining a Buy rating.
The analyst comments "UroGen disclosed strong ENVISION 12-month DoR data (82.3%) at an investor event on June 13, 2024; Rolling NDA submission expected to complete by September 2024; Potential approval as soon as 1Q25, with priority... More
Goldman Sachs Reiterates Neutral Rating on UroGen Pharma (URGN)
June 14, 2024 5:11 AM EDTGoldman Sachs analyst Paul Choi reiterated a Neutral rating and $22.00 price target on UroGen Pharma (NASDAQ: URGN).
The analyst comments "Encouraging data for UGN-102 far exceeded expectations on 12-month durability of response; focus shifting to regulatory filing and subsequent launch execution. URGN is outperforming today (+41%... More
